Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration

被引:24
作者
Bellmann, R [1 ]
Egger, P
Djanani, A
Wiedermann, CJ
机构
[1] Univ Innsbruck, Med Intens Care Res Lab, Clin Pharmacokinet Unit, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Dept Internal Med, Div Gen Internal Med, Intens Care Unit, A-6020 Innsbruck, Austria
关键词
amphotericin B lipid complex; ABLC; abelcet; lipid-formulated amphotericin B; pharmacokinetics; continuous veno-venous haemofiltration;
D O I
10.1016/j.ijantimicag.2003.05.014
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pharmacokinetics of amphotericin B lipid complex (ABLC) was determined in two critically ill patients requiring continuous veno-venous haemofiltration (CVVH) because of acute renal failure. ABLC was administered at a mean daily dose of 4.94 mg/kg for suspected invasive mycosis. Mean C-max was 0.56 mug/ml, the mean AUC(0-24 h) was 7.46 mg h/I, V-SS 9.131/kg, and t(1/2) was 13.21 h. The haemofilter clearance accounted about 20% of the total ABLC clearance. In one patient sampling was repeated after CVVH had been discontinued. The concentration-time profiles were very similar on and off haemofiltration. Data on our two patients suggest, that pharmacokinetics of ABLC is not significantly affected by CVVH and that ABLC can be administered at the standard doses during CVVH. (C) 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:80 / 83
页数:4
相关论文
共 28 条
  • [1] A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections
    Adedoyin, A
    Swenson, CE
    Bolcsak, LE
    Hellmann, A
    Radowska, D
    Horwith, G
    Janoff, AS
    Branch, RA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (10) : 2900 - 2902
  • [2] Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies
    Adedoyin, A
    Bernardo, JF
    Swenson, CE
    Bolsack, LE
    Horwith, G
    DeWit, S
    Kelly, E
    Klasterksy, J
    Sculier, JP
    DeValeriola, D
    Anaissie, E
    LopezBerestein, G
    LlanosCuentas, A
    Boyle, A
    Branch, RA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) : 2201 - 2208
  • [3] Adler-Moore J.P., 1993, Journal of Liposome Research, V3, P429, DOI DOI 10.3109/08982109309150729
  • [4] Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration
    Bellmann, R
    Egger, P
    Gritsch, W
    Bellmann-Weiler, R
    Joannidis, M
    Kaneider, N
    Dunzendorfer, S
    Wiedermann, CJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (03) : 671 - 681
  • [5] AmBisome (Liposomal amphotericin B): A comparative review
    Boswell, GW
    Buell, D
    Bekersky, I
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (07) : 583 - 592
  • [6] DAMELIO LF, 1995, AM SURGEON, V61, P1049
  • [7] deMarie S, 1996, LEUKEMIA, V10, pS93
  • [8] Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography
    Egger, P
    Bellmann, R
    Wiedermann, CJ
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2001, 760 (02): : 307 - 313
  • [9] Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial
    Eriksson, U
    Seifert, B
    Schaffner, A
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7286): : 579 - 582
  • [10] Amphotericin B-induced nephrotoxicity: A review
    Fanos, V
    Cataldi, L
    [J]. JOURNAL OF CHEMOTHERAPY, 2000, 12 (06) : 463 - 470